Intensive 3-day course on Transformative Approaches in Medicinal Chemistry, with Applications in Cancer Research.
Course Outline
Technologies for drug discovery are constantly evolving. Significant developments within the last 20 years range from the development of DNA-encoded libraries for hit finding and even hit-to-lead optimization to the reinvigoration of irreversible inhibitors resulting in innovative oncology drugs such as osimertinib and sotorasib.
This course will cover advanced methods, new technologies, and tools available for medicinal chemists, with a focus on oncology drug discovery, including fragment based-drug discovery, DNA-encoded library technologies, covalent drug discovery and small molecules that target RNA. The course will finish with a series of oncology case studies successfully using these drug discovery technologies for the development of clinical candidates and marketed drugs.
Course Set-up
The course is intended for scientists working in the field, and the presentations will be given by senior scientists from industry and academia. The number of participants is limited to 35, to allow in depth discussion. Should the number of applications exceed the maximum, preference will be given to applicants from EFMC adhering countries and employees of EFMC corporate members.
Upon special request to the organisers, only based on financial conditions and supported by an argued recommendation of the head of the department of the applicant, up to three applicants from academia may be admitted at a reduced fee.
Confirmed Speakers
- Dr Frederic BERST, NOVARTIS, Basel, Switzerland
- Dr Gerjan DE BRUIN, ACERTA PHARMA, Oss, The Netherlands
Design of multifunctional conjugates for the targeting of non-coding RNAs: anticancer and antimicrobial applications - Dr Maria DUCA, UNIVERSITY OF CÔTE D’AZUR, Nice, France
- Dr Christoph DUMELIN, NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (SWITZERLAND) (NIBR), Basel, Switzerland
What can we learn from 20+ years of FBDD and what are the future opportunities? - Dr Christopher JOHNSON, ASTEX PHARMACEUTICALS, Cambridge, United Kingdom
- Dr Hannah STEWART, NEWCASTLE UNIVERSITY, Newcastle Upon Tyne, United Kingdom
- Prof. Mike WARING, NEWCASTLE UNIVERSITY, Newcastle upon Tyne, United Kingdom
